Clinical Features, Molecular Diagnosis, and Treatment Outcome of Infants with Leukemia in Taiwan

被引:11
作者
Chen, Shih-Hsiang
Yang, Chao-Ping [1 ]
Hung, Iou-Jih
Jaing, Tang-Her
Shih, Lee-Yung [2 ]
Tsai, Ming-Horng [3 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Pediat,Div Hematol Oncol, Tao Yuan 333, Taiwan
[2] Chang Gung Mem Hosp, Div Hematol Oncol, Dept Internal Med, Tao Yuan, Taiwan
[3] Chang Gung Mem Hosp, Dept Pediat, Chiayi, Taiwan
关键词
infant leukemia; MLL gene rearrangement; prognosis; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; MLL GENE; PROGNOSTIC-FACTORS; ALL-1; GENE; B-LINEAGE; CHILDHOOD; CHILDREN; THERAPY;
D O I
10.1002/pbc.22731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Infant leukemia is rare and quite distinct from other childhood leukemias Differentiating between leukemia and transient myeloproliferative disorder (TMD) in phenotypically normal infants is sometimes difficult The clinical features and molecular analyses for the fusion transcripts of mixed lineage leukemia (MLL) gene rearrangement in infant leukemia hive not been well documented in the Chinese population Procedure Forty five consecutive infants diagnosed with leukemia between 1995 and 2007 in a tertiary medical center in Taiwan were studied Acute lymphoblastic leukemia (ALL) was diagnosed in 23 infants acute myeloid leukemia (AML) in 21 (including TMD in 4) and juvenile myelomonocytic leukemia (JMML) in 1 Results The median white count at diagnosis was higher in ALL than in AML (154 4 x 10(9)/l vs 58 3 x 10(9)/l P=0 05) Chromosome 11q23/MLL abnormalities were present in 77% of ALL and 31% of AML The 5 year event free survival (EFS) in infant ALL and AML showed no difference (18% vs 12% respectively) The only independent predictor of an adverse prognosis among infants diagnosed with ALL was high presenting white count >= 100 x 10(9)/l (P=0 05) However no factor was associated with an adverse outcome for infants with AML Conclusions The molecular assessments and prognostic factors of infant leukemia in Taiwan mirror those in developed Western countries Continued molecular investigations and development of more effective therapies are needed Pediatr Blood Cancer 2010,55 1264-1271 (C) 2010 Wiley Liss Inc
引用
收藏
页码:1264 / 1271
页数:8
相关论文
共 49 条
  • [1] Juvenile myelomonocytic leukemia
    Arico, M
    Biondi, A
    Pui, CH
    [J]. BLOOD, 1997, 90 (02) : 479 - 488
  • [2] Biological and therapeutic aspects of infant leukemia
    Biondi, A
    Cimino, G
    Pieters, R
    Pui, CH
    [J]. BLOOD, 2000, 96 (01) : 24 - 33
  • [3] Caligiuri MA, 1996, CANCER RES, V56, P1418
  • [4] Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party
    Chessells, JM
    Harrison, CJ
    Kempski, H
    Webb, DKH
    Wheatley, K
    Hann, IM
    Stevens, RF
    Harrison, G
    Gibson, BE
    [J]. LEUKEMIA, 2002, 16 (05) : 776 - 784
  • [5] CIMINO G, 1995, LEUKEMIA, V9, P391
  • [6] CIMINO G, 1993, BLOOD, V82, P544
  • [7] Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98
    Creutzig, U
    Zimmermann, M
    Reinhardt, D
    Dworzak, M
    Stary, J
    Lehrnbecher, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4384 - 4393
  • [8] CRIST WM, 1985, BLOOD, V66, P33
  • [9] Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
    Dördelmann, M
    Reiter, A
    Borkhardt, A
    Ludwig, WD
    Götz, N
    Viehmann, S
    Gadner, H
    Riehm, H
    Schrappe, M
    [J]. BLOOD, 1999, 94 (04) : 1209 - 1217
  • [10] Molecular analysis of t(X;II)(q24;q23) in an infant with AML-M4
    Fu, JF
    Liang, DC
    Yang, CP
    Hsu, JJ
    Shih, LY
    [J]. GENES CHROMOSOMES & CANCER, 2003, 38 (03) : 253 - 259